Smoke rises from fire at a site of Serum Institute of India in Pune, Maharashtra state, India. Picture: PUNE CITY NEWS/Handout via Reuters
Smoke rises from fire at a site of Serum Institute of India in Pune, Maharashtra state, India. Picture: PUNE CITY NEWS/Handout via Reuters

Fire breaks out at Serum Institute of India, but Covid-19 vaccine production not affected

By AFP, Reuters Time of article published Jan 21, 2021

Share this article:

Ammu Kannampilly

Mumbai - A fire broke out Thursday at India's Serum Institute, the world's largest maker of vaccines, but a company source said production of drugs to prevent coronavirus was not affected.

"I would like to reassure all governments & the public that there would be no loss of Covishield production due to multiple production buildings that I had kept in reserve to deal with such contingencies," Chief Executive Adar Poonawalla said on Twitter.

The Serum Institute is producing millions of doses of the Covishield coronavirus vaccine, developed by AstraZeneca and Oxford University, for India and many other countries, including South Africa.

Local TV channels showed thick clouds of grey smoke billowing from the sprawling site in Pune, in western India.

"It is not going to affect production of the Covid-19 vaccine," a source at the Serum Institute told AFP, adding that the blaze was at a new plant under construction.

An official at the local fire station told AFP that six or seven fire trucks had reached the site, spread over 100 acres (40 hectares).

Three people were reported to have been rescued from the blaze, with another unaccounted for.

"Thick smoke is hampering the work of bringing the fire under control," the fire brigade told NDTV.

The complex where the fire broke out is a few minutes drive from the facility where the coronavirus vaccines are produced, reports said.

Eight or nine buildings are under construction at the complex to enhance its manufacturing capability, NDTV reported.

Serum Institute - founded in 1966 by Cyrus Poonawalla - is the world's largest vaccine manufacturer by volume, producing 1.5 billion doses a year even before the coronavirus pandemic.

It makes vaccines against polio, diphtheria, tetanus, hepatitis B, measles, mumps and rubella, which are exported to more than 170 countries.

The company has spent nearly a billion dollars in recent years enlarging and improving the giant Pune campus.

In January, Indian regulators approved two vaccines -- Covishield, produced by the Serum Institute, and Covaxin, made by local firm Bharat Biotech.

India began one of the world's biggest vaccine rollouts on Saturday, aiming to vaccinate 300 million people by July with both Covishield and Covaxin.

Many other countries are relying on the Serum Institute to supply them with the vaccine.

South Africa is due to procure 1.5 million of the shots from the institute.

India exported its first batch on Wednesday -- to Bhutan and the Maldives -- followed by two million doses to Bangladesh and a million to Nepal.

The country plans to offer 20 million doses to its South Asian neighbours, with Latin America, Africa and Central Asia next in line.

Serum Institute also plans to supply 200 million doses to Covax, a World Health Organization-backed effort to procure and distribute inoculations to poor countries.

Brazil last weekend was set to send a plane to collect two million doses from Serum but President Jair Bolsonaro said that "political pressure" in India had postponed the flight.

Serum chief Adar Poonawalla told the Times of India it would supply Brazil in two weeks.

Share this article:

Related Articles